Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

HeartMate 3 LVAD

With Full Maglev Flow Technology

About HeartMate 3 LVAD

The HeartMate​ 3™​ Left Ventricular Assist Device (LVAD) is a mechanical circulatory support device designed for patients with advanced heart failure. With significantly improved outcomes and survival comparable to heart transplant at 2 years1-3 and 5 years,4-7our LVAD device technology is making a better future possible for many patients with advanced heart failure.*1-3 The HeartMate​ 3 LVAD has advanced the field of LVAD therapy and is setting the standard with innovation and outstanding clinical outcomes.1
 

The Full MagLev Flow Technology within the HeartMate 3 LVAD maintains gentle blood handling to minimize complications and hemocompatibility-related adverse events.

HeartMate 3 LVAD with Full MagLev Flow Technology Pump offers:

  • Fully levitated, self-centering rotor that does not require hydrodynamic or mechanical bearings
  • Large, consistent blood flow pathways, which reduces shear stress8
  • Intrinsic pulsatility to reduce stasis and minimize thrombus8,9
     
Cut across view of the HeartMate 3 Maglev Pump
Product details

HeartMate 3 LVAD Information

Indications:

The HeartMate 3 Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

Contraindications:

The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

HeartMate 3 LVAD Clinical Evidence

There are comprehensive clinical evidence materials available to learn about the survival rate and patient improvement associated with the HeartMate 3 LVAD. For a deep dive into the clinical data, visit the Clinical Evidence and Momentum 3 Trial information.


MOMENTUM 3 5-Year Outcomes

MOMENTUM 3 is the largest LVAD trial ever conducted demonstrating excellent survival and safety outcomes with HeartMate 3™ LVAD.**1


HEARTMATE 3™ LVAD, a proven long-term, life-extending therapy for patients with advanced heart failure

Median survival
exceeding
5 years4

58.4%
survival at
5 years4

Improved Safety Profile5

The ELEVATE Registry5 evaluated the real-world experience of the HeartMate 3 LVAD in a post-approval setting. 5-year extended follow-up showed:
 

Stroke
10.8% in first 2 years
3.6% in years 2-5

Thrombosis
1.1% at 5 years

All major event types were reduced in the 2-5 years follow-up period compared to 0-2 years, especially hemocompatibility-related adverse events.

HeartMate 3 LVAD Education and Training

For the safe and effective management of advanced heart failure with the HeartMate 3 LVAD, we provide comprehensive educational resources. The following resources are designed to help you better understand patient education, use cases, surgical procedure and more.

Reimbursement & Coding

For the full resource list, visit Reimbursement & Coding for left ventricular assist devices.

Manuals & Resources

Manuals & Resources

Find a HeartMate 3 LVAD Center

Find a HeartMate 3 LVAD Center

Customer Service

Customer Service

*Based on published data from separate datasets, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.
**HeartMate 3 LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
§For a continuous-flow LVAD in a randomized controlled trial.
 

References

  1. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
  2. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplant Report-2018; Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018;37:1155-1168.
  3. Teuteberg JJ, Cleveland JC Jr, Cowger J, et al. The Society of Thoracic Surgeons Intermacs 2019 Annual Report: The Changing Landscape of Devices and Indications. Ann Thorac Surg. March 2020;109(3):649-660.
  4. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. JAMA. 2022;328(12):1233-1242. doi:10.1001/jama.2022.16197.
  5. Schmitto JD, Shaw S, Garbade J, et al. Long-Term Results in Real World Patients Treated with HeartMate 3 LVAD for Advanced Heart Failure: Data from the ELEVATE Registry. European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting; October 8, 2022; Milan, Italy.
  6. Jorde UP, Saeed O, Koehl D, et al. The Society of Thoracic Surgeons Intermacs 2023 Annual Report: Focus on Magnetically Levitated Devices. Ann Thorac Surg 2024;117(1):33-44. doi:10.1016/j.athoracsur.2023.11.004.
  7. Nayak A, Hall SA, Uriel N, et al. Predictors of 5-Year Mortality in Patients Managed With a Magnetically Levitated Left Ventricular Assist Device. J Am Coll Cardiol 2023;82(9):771-781. doi:10.1016/j.jacc.2023.05.066.
  8. Bourque K, Cotter C, Dague C, et al. Design rationale and preclinical evaluation of the HeartMate 3 Left Ventricular Assist System for hemocompatibility. Am Soc Artificial Int Organs. 2016;62:375-383.
  9. Bourque K, Dague C, Farrar D, et al. In vivo assessment of a rotary left ventricular assist device-induced artificial pulse in the proximal and distal aorta. Artificial Organs. 2006;30:638-642.

MAT-2012548 v4.0